Evidence map›Paper›PMID 42178559›Full record

ArticleJournal of nanobiotechnology2026

Self-fueling catalysis-driven membrane destabilization triggers CSC-enriched tumors ablation.

Lin Huang, Basheng Hu, Guochao Wu, Wenjie Ma, Jiaoyang Qiu, Jiaoyang Zhu, Jing Yang, Haobin Cai, Qingdeng Fan, Bin Ren and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lin HuangCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, Guangdong, China.
Basheng HuMedical Imaging Center, Nanfang Hospital, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China. hubsh1@smu.edu.cn.
Guochao WuSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Wenjie MaSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Jiaoyang QiuSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Jiaoyang ZhuSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Jing YangSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Haobin CaiSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Qingdeng FanSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Bin RenSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Chunmei ChenSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Zehui WangSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Jie FengMedical Imaging Center, Nanfang Hospital, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Yitong LiBreast Surgery, Nanfang Hospital, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Sugeun YangDepartment of Biomedical Science, BK21FOURProgram in Biomedical Science and Engineering, Inha University College of Medicine, Incheon, 22212, South Korea.
Chenggong YanMedical Imaging Center, Nanfang Hospital, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China.
Xiangrong YuDepartment of Radiology, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan University, Zhuhai, 519000, China. yuxiangrong@jnu.edu.cn.
Zhigang LiuCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523059, Guangdong, China. zhigangliu1983@hotmail.com.
Zheyu ShenSchool of Biomedical Engineering, Southern Medical University, 1023 Sha-Tai South Road, Guangzhou, 510515, Guangdong, China. sz@smu.edu.cn.

Funding

Dongguan Science and Technology of Social Development Program 20231800932392Guangdong Basic and Applied Basic Research Foundation 2024A1515012639Guangzhou Key Research and Development Program of China 2025B01J3007National Natural Science Foundation of China 32271374National Natural Science Foundation of China 32501164National Natural Science Foundation of China 82071915
6 · The paper itself

Abstract

Eradication of cancer stem cells (CSC) enriched tumors remains a formidable challenge due to their intrinsic drug resistance and robust cholesterol-driven anti-ferroptotic defenses. Herein, we report a cholesterol oxidase (COD)-loaded hollow mesoporous zinc-copper sulfide (COD@HMZCS-HA) nanomedicine designed to eliminate CSC via self-fueling catalysis-driven membrane destabilization. After targeted tumor accumulation, the released components function synergistically to overcome therapeutic resistance. Specifically, COD-mediated cholesterol depletion acts as an indispensable sensitizing step by dismantling the biophysical membrane barrier of protective lipid rafts and inactivating the 7-dehydrocholesterol (7-DHC)-mediated endogenous "molecular brake" on LPO. Concurrently, a self-fueling catalytic cycle, involving Cu

Indexed as

Antineoplastic AgentsNeoplastic Stem CellsAnimalsCatalysisCell Line, TumorCholesterolCholesterol OxidaseCopperFerroptosisHumansMiceSulfidesZincAntineoplastic AgentsCholesterolCholesterol OxidaseCopperSulfidesZincCancer stem cellsCholesterol-dependent membrane defensesFerroptosis amplification and propagationHollow mesoporous zinc-copper sulfide nanocapsulesSelf-fueling catalysis

Identifiers

PMID42178559
PMCPMC13383432

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.